Antagonizing Increased miR-135a Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures

Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disease characterized by recurrent seizures. The antiepileptic drugs currently available to treat mTLE are ineffective in one-third of patients and lack disease-modifying effects. miRNAs, a class of small noncoding RNAs which control gen...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 39; no. 26; pp. 5064 - 5079
Main Authors Vangoor, Vamshidhar R, Reschke, Cristina R, Senthilkumar, Ketharini, van de Haar, Lieke L, de Wit, Marina, Giuliani, Giuliano, Broekhoven, Mark H, Morris, Gareth, Engel, Tobias, Brennan, Gary P, Conroy, Ronan M, van Rijen, Peter C, Gosselaar, Peter H, Schorge, Stephanie, Schaapveld, Roel Q J, Henshall, David C, De Graan, Pierre N E, Pasterkamp, R Jeroen
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 26.06.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disease characterized by recurrent seizures. The antiepileptic drugs currently available to treat mTLE are ineffective in one-third of patients and lack disease-modifying effects. miRNAs, a class of small noncoding RNAs which control gene expression at the post-transcriptional level, play a key role in the pathogenesis of mTLE and other epilepsies. Although manipulation of miRNAs at acute stages has been reported to reduce subsequent spontaneous seizures, it is uncertain whether targeting miRNAs at chronic stages of mTLE can also reduce seizures. Furthermore, the functional role and downstream targets of most epilepsy-associated miRNAs remain poorly understood. Here, we show that is selectively upregulated within neurons in epileptic brain and report that targeting using antagomirs after onset of spontaneous recurrent seizures can reduce seizure activity at the chronic stage of experimental mTLE in male mice. Further, by using an unbiased approach combining immunoprecipitation and RNA sequencing, we identify several novel neuronal targets of , including Mef2 proteins are key regulators of excitatory synapse density. Mef2a and show reciprocal expression regulation in human (of both sexes) and experimental TLE, and regulates dendritic spine number and type through Mef2. Together, our data show that is target for reducing seizure activity in chronic epilepsy, and that deregulation of in epilepsy may alter expression and thereby affect synaptic function and plasticity. miRNAs are post-transcriptional regulators of gene expression with roles in the pathogenesis of epilepsy. However, the precise mechanism of action and therapeutic potential of most epilepsy-associated miRNAs remain poorly understood. Our study reveals dramatic upregulation of the key neuronal miRNA in both experimental and human mesial temporal lobe epilepsy. Silencing in experimental temporal lobe epilepsy reduces seizure activity at the spontaneous recurrent seizure stage. These data support the exciting possibility that miRNAs can be targeted to combat seizures after spontaneous seizure activity has been established. Further, by using unbiased approaches novel neuronal targets of , including members of the Mef2 protein family, are identified that begin to explain how deregulation of may contribute to epilepsy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
C.R.R. and K.S. contributed equally to this work.
Author contributions: V.R.V., C.R.R., K.S., L.L.v.d.H., G.G., G.M., D.C.H., P.N.E.D.G., and R.J.P. designed research; V.R.V., C.R.R., K.S., L.L.v.d.H., M.d.W., G.G., M.H.B., G.M., T.E., and G.P.B. performed research; V.R.V., C.R.R., K.S., L.L.v.d.H., M.d.W., G.G., M.H.B., G.M., G.P.B., R.M.C., and R.J.P. analyzed data; V.R.V. and R.J.P. wrote the paper; P.C.v.R., P.H.G., S.S., and R.Q.J.S. contributed unpublished reagents/analytic tools.
ISSN:0270-6474
1529-2401
DOI:10.1523/JNEUROSCI.3014-18.2019